178 related articles for article (PubMed ID: 19786840)
21. Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
Delaloye J; Filali-Mouhim A; Cameron MJ; Haddad EK; Harari A; Goulet JP; Gomez CE; Perdiguero B; Esteban M; Pantaleo G; Roger T; Sékaly RP; Calandra T
J Virol; 2015 Apr; 89(7):3819-32. PubMed ID: 25609807
[TBL] [Abstract][Full Text] [Related]
22. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
Franchini G; Gurunathan S; Baglyos L; Plotkin S; Tartaglia J
Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S75-88. PubMed ID: 15285707
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
[TBL] [Abstract][Full Text] [Related]
24. Clinical applications of attenuated MVA poxvirus strain.
Gómez CE; Perdiguero B; García-Arriaza J; Esteban M
Expert Rev Vaccines; 2013 Dec; 12(12):1395-416. PubMed ID: 24168097
[TBL] [Abstract][Full Text] [Related]
25. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
26. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
Volz A; Sutter G
Vaccine; 2013 Sep; 31(39):4235-40. PubMed ID: 23523402
[TBL] [Abstract][Full Text] [Related]
27. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes.
Dai K; Liu Y; Liu M; Xu J; Huang W; Huang X; Liu L; Wan Y; Hao Y; Shao Y
Vaccine; 2008 Sep; 26(39):5062-71. PubMed ID: 18573290
[TBL] [Abstract][Full Text] [Related]
28. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
[TBL] [Abstract][Full Text] [Related]
29. Highly attenuated poxvirus vectors.
Tartaglia J; Cox WI; Taylor J; Perkus M; Riviere M; Meignier B; Paoletti E
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1445-7. PubMed ID: 1466978
[No Abstract] [Full Text] [Related]
30. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
Amara RR; Villinger F; Staprans SI; Altman JD; Montefiori DC; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McClure HM; Moss B; Robinson HL
J Virol; 2002 Aug; 76(15):7625-31. PubMed ID: 12097576
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
Chea LS; Amara RR
Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
[TBL] [Abstract][Full Text] [Related]
32. Poxvirus vectors as HIV/AIDS vaccines in humans.
Gómez CE; Perdiguero B; Garcia-Arriaza J; Esteban M
Hum Vaccin Immunother; 2012 Sep; 8(9):1192-207. PubMed ID: 22906946
[TBL] [Abstract][Full Text] [Related]
33. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.
Boukhebza H; Bellon N; Limacher JM; Inchauspé G
Hum Vaccin Immunother; 2012 Dec; 8(12):1746-57. PubMed ID: 22894957
[TBL] [Abstract][Full Text] [Related]
35. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.
Price PJ; Torres-Domínguez LE; Brandmüller C; Sutter G; Lehmann MH
Vaccine; 2013 Sep; 31(39):4231-4. PubMed ID: 23523404
[TBL] [Abstract][Full Text] [Related]
36. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
37. Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Kent S; De Rose R; Rollman E
Curr Opin Investig Drugs; 2007 Feb; 8(2):159-67. PubMed ID: 17328232
[TBL] [Abstract][Full Text] [Related]
38. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
Lorenzo MM; Nogales A; Chiem K; Blasco R; Martínez-Sobrido L
Microbiol Spectr; 2022 Jun; 10(3):e0027222. PubMed ID: 35583360
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
[TBL] [Abstract][Full Text] [Related]
40. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
Paris RM; Kim JH; Robb ML; Michael NL
Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
